Asset Details
Do you wish to reserve the book?
Inflammatory arthritis and malignancy: A consensus report on risk assessment and clinical management based on a systematic review from the Turkish Society of Rheumatology Malignancy Study Group
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inflammatory arthritis and malignancy: A consensus report on risk assessment and clinical management based on a systematic review from the Turkish Society of Rheumatology Malignancy Study Group
Do you wish to request the book?
Inflammatory arthritis and malignancy: A consensus report on risk assessment and clinical management based on a systematic review from the Turkish Society of Rheumatology Malignancy Study Group
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inflammatory arthritis and malignancy: A consensus report on risk assessment and clinical management based on a systematic review from the Turkish Society of Rheumatology Malignancy Study Group
2025
Overview
Inflammatory arthritis (IA) is associated with an increased risk for certain malignancies, particularly lymphoma, due to underlying chronic inflammation. Conventional and targeted therapies used in IA modulate the immune system, raising concerns about the development of de novo malignancies or the progression of pre-existing ones. Managing IA patients with a history of cancer remains one of the most challenging areas for clinicians, and while international guidelines exist, they generally focus on a narrower scope. This report is the first comprehensive consensus report from Türkiye to address the relationship between IA and malignancy across a wide spectrum, including baseline risk, treatment-related risk, management of patients with a history of cancer, treatment during active malignancy, premalignant lesions, and family history. Based on a systematic literature review, this report provides evidence-based, practical recommendations for specific scenarios frequently encountered in daily practice—such as cancer development during active treatment, premalignant lesions, and family history—which are often narrowly addressed in existing international guidelines. This report will help rheumatologists standardize decision-making processes regarding the coexistence of IA and malignancy, enabling them to take safer clinical steps. By promoting risk individualization and shared decision-making between patients and clinicians, it will strengthen personalized treatment approaches that ensure both effective control of rheumatic disease and oncologic safety.
Publisher
Turkish Society for Rheumatology
